The medical world is buzzing with anticipation as Moderna, a leading pharmaceutical company, announced groundbreaking progress towards a combined flu and COVID-19 vaccine. This potential game-changer could revolutionise the way we approach vaccination against these two significant respiratory illnesses.
In a recent study involving over 8,000 adults aged 50 and above, Moderna’s innovative combination vaccine showed promising results. The study compared the immune responses of individuals who received the combined COVID-19 and influenza shot with those who were administered separate vaccines for each disease. The findings revealed that the combination vaccine triggered even better immune responses against SARS-CoV-2 and influenza compared to the individual vaccines.
The unique aspect of Moderna’s combination vaccine lies in its composition. The COVID-19 component of the vaccine utilises a modified form of SARS-CoV-2’s spike protein, different from the traditional vaccine. By incorporating two crucial parts of the spike protein, the combination vaccine can achieve superior immune responses with a lower dosage. This streamlined approach not only enhances the vaccine’s effectiveness but also potentially extends its shelf life, presenting a significant advantage in vaccine distribution and storage.
Moreover, the influenza component of the vaccine harnesses the same mRNA technology employed in Moderna’s COVID-19 vaccine. Targeting influenza proteins from three prevalent strains – H1N1, H3N2, and an influenza B strain circulating during the previous season – the combination vaccine demonstrates a comprehensive approach to combatting multiple strains of the flu virus.
The results of the study are promising, particularly in terms of antibody response levels. Individuals in the younger age group who received the combo vaccine exhibited 20% to 40% higher antibody levels against influenza strains and 30% higher levels against XBB.1.5 compared to the control group. Similarly, older participants showed increased antibody levels ranging from 6% to 15% against flu strains and a substantial 64% rise against XBB.1.5 when compared to their counterparts who received separate vaccines.
Experts believe that the convenience of a single-shot regimen could significantly impact public health efforts. Dr Jacqueline Miller, Senior Vice President and Head of Development in Infectious Diseases at Moderna, in the public release, emphasised the advantage of streamlining vaccination processes. She highlighted that a unified flu and COVID-19 vaccine could enhance compliance rates, especially among high-risk populations, ultimately leading to improved vaccination coverage and reduced hospitalisation rates for both diseases.
Moderna’s ongoing research extends beyond the combination vaccine. The company continues to investigate the individual efficacy of its COVID-19 vaccine and the flu shot included in the combination regimen. This comprehensive approach will provide valuable data to support Moderna’s application for FDA approval of the combined vaccine, anticipated by the end of this year.
While the combined flu and COVID-19 vaccine may not be available in time for the upcoming flu season, its potential impact in future vaccination campaigns is substantial. By simplifying vaccination procedures and improving accessibility, a two-in-one vaccine has the potential to transform public health strategies and contribute to mitigating the burden of respiratory illnesses.
Moderna’s pioneering efforts in developing a combined flu and COVID-19 vaccine represent a significant leap forward in preventive healthcare. As we navigate ongoing challenges posed by infectious diseases, innovative solutions like these offer hope for a healthier future.
